Psychobiological Mechanisms Underlying Chronic Pain

NACompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions
FibromyalgiaPain, ChronicChronic Pain, Widespread
Interventions
DRUG

Bromocriptine Mesylate Capsules

Healthy controls and fibromyalgia patients will be administered a single dose of bromocriptine (1.25mg, p.o.) to investigate the effect of transiently increasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.

DRUG

Amisulpride 400 MG

Healthy controls will be administered a single dose of amisulpride (400mg, p.o.) to investigate the effect of transiently decreasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.

DRUG

Placebo

Healthy controls and fibromyalgia patients will be administered a placebo as for comparison with the effects of bromocriptine (healthy controls and patients) and amisulpride (healthy controls only) on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.

Trial Locations (1)

8008

Balgrist Campus, Zurich

All Listed Sponsors
collaborator

SNSF

UNKNOWN

lead

susanne becker

OTHER

NCT04674670 - Psychobiological Mechanisms Underlying Chronic Pain | Biotech Hunter | Biotech Hunter